ClinicalTrials.gg
RecruitingNCT05147701Updated Oct 16, 2026

Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Exosomes for NAION

A Phase 1 interventional study of cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cell exosomes in Eye Diseases, Retinitis Pigmentosa and Diabetic Retinopathy, sponsored by The Foundation for Orthopaedics and Regenerative Medicine. Recruiting at 2 sites in 2 countries. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by The Foundation for Orthopaedics and Regenerative Medicine · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2022; still recruiting 4 years 9 months later.
Updated Oct 16, 2026First sites in Greece and United StatesNo longer in Antigua and Barbuda and Argentina+7 moreGo to Updates ↓
Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Sex
All
01

Study summary

This trial will study the safety and efficacy of intranasal delivery of cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cell exosomes for the treatment of non-arteritic ischemic optic neuropathy

Read the detailed description

This patient funded trial aims to study the safety and efficacy of intranasal delivery of cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cell exosomes for the treatment of non-arteritic ischemic optic neuropathy. The total dose will be 100 million cells. Patients will be evaluated within one month pre treatment and at 1, 6, 12, 24, 36, and 48 months post treatment for safety and efficacy.

02

Conditions studied

  • Eye Diseases
  • Retinitis Pigmentosa
  • Diabetic Retinopathy
  • Macular Degeneration
  • Traumatic Optic Neuropathy
  • Optic Atrophy

Keywords

  • Eye Diseases
  • Retinitis Pigmentosa
  • stem cell treatment
  • Diabetic Retinopathy
  • Macular Degeneration
  • Traumatic Optic Neuropathy
  • Optic Atrophy
03

In context

Eye Diseases

388 studies on the registry are indexed under Eye Diseases; 62 are open to participants now.

This study's planned enrollment of 20 is below the median of 62 across 269 interventional studies indexed under Eye Diseases.

Browse Eye Diseases studies →

Lead sponsor

The Foundation for Orthopaedics and Regenerative Medicine is the lead sponsor of 33 studies on the registry; 20 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of NAION (non-arteritic ischemic optic neuropathy)
  • Understanding and willingness to sign a written document

Exclusion criteria

Exclusion Criteria:

  • Active infection
  • Active cancer
  • Chronic multisystem organ failure
  • Pregnancy
  • Abnormalities on pre-treatment laboratory evaluation
  • Medical condition that would (based on the opinion of the investigator) compromise patient's safety.
  • Continued drug abuse
  • Pre-menopausal women not using
  • Previous organ transplant
  • to sulfur
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Treatment Group

    Intranasal delivery

    Biological: cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cell exosomes

Interventions

  • Biologicalcultured allogeneic adult umbilical cord or placental derived mesenchymal stem cell exosomes

    cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cell exosomes

06

What researchers measure

Primary outcomes

  1. Safety (adverse events)

    Clinical monitoring of possible adverse events or complications

    Time frame: Four year follow-up

07

Study locations

2 of 2 sites recruiting
08

References and documents

Publications

  • Sung Y, Lee SM, Park M, Choi HJ, Kang S, Choi BI, Lew H. Treatment of traumatic optic neuropathy using human placenta-derived mesenchymal stem cells in Asian patients. Regen Med. 2020 Oct;15(10):2163-2179. doi: 10.2217/rme-2020-0044. Epub 2020 Dec 14. PubMed 33315474 ↗
  • Zhao T, Liang Q, Meng X, Duan P, Wang F, Li S, Liu Y, Yin ZQ. Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells Maintains and Partially Improves Visual Function in Patients with Advanced Retinitis Pigmentosa. Stem Cells Dev. 2020 Aug;29(16):1029-1037. doi: 10.1089/scd.2020.0037. Epub 2020 Jul 15. PubMed 32679004 ↗
  • Ozmert E, Arslan U. Management of retinitis pigmentosa by Wharton's jelly derived mesenchymal stem cells: preliminary clinical results. Stem Cell Res Ther. 2020 Jan 13;11(1):25. doi: 10.1186/s13287-020-1549-6. PubMed 31931872 ↗
09

Updates

1 registry update since Sep 25, 2026
Sites
2 sites added, 2 sites removed — first sites in Greece and United States; no longer in Antigua and Barbuda and Argentina
Show 2 added (1 United States, 1 Greece)
  • Prodromos Stem Cell Institute · Naples, United States
  • Prodromos Stem Cell Institute · Athens, Greece
Show 2 removed
  • Medical Surgical Associates Center · St. John's, Antigua and Barbuda
  • Center for Investigation in Tissue Engineering and Cellular Therapy · Buenos Aires, Argentina
Oct 16, 2026
Primary completion
Jan 2026→Jan 2028
Oct 16, 2026
Study completion
Jan 2026→Jan 2028
Oct 16, 2026
Interventions
Added Biological: cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cell exosomes; removed Biological: AlloRx. Arm changed Treatment Group (AlloRx)→Treatment Group
Oct 16, 2026
Contact
Study contact now listed: added c•••@thepsci.com · •••6810. See the current contact
Oct 16, 2026
Title
Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem CellsCell Exosomes for NAION
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    2 sites added, 2 sites removed — first sites in Greece and United States; no longer in Antigua and Barbuda and Argentina
    Show 2 added (1 United States, 1 Greece)
    • Prodromos Stem Cell Institute · Naples, United States
    • Prodromos Stem Cell Institute · Athens, Greece
    Show 2 removed
    • Medical Surgical Associates Center · St. John's, Antigua and Barbuda
    • Center for Investigation in Tissue Engineering and Cellular Therapy · Buenos Aires, Argentina
    Primary completion Jan 2026→Jan 2028
    Study completion Jan 2026→Jan 2028
    Interventions Added Biological: cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cell exosomes; removed Biological: AlloRx. Arm changed Treatment Group (AlloRx)→Treatment Group
    Contact Study contact now listed: added c•••@thepsci.com · •••6810. See the current contact
    Title Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem CellsCell Exosomes for NAION
    + 4 other changes: verification date, description, data sharing statement and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05147701
Lead sponsor
The Foundation for Orthopaedics and Regenerative Medicine
Responsible party
Sponsor
First posted
Dec 7, 2021
Start date
Feb 1, 2022
Primary completion
Jan 2028 (estimated)
Completion
Jan 2028 (estimated)
Last update
Oct 16, 2026

Study contacts

Chadwick Prodromos, MD
Contact
care@thepsci.com
847-699-6810 ext. 202

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion